Full coverage· Health· Updated
Chinese Cancer Drugs Show Promise Against Chemotherapy
Two new Chinese cancer drugs, sacituzumab tirumotecan and izalontamab brengitecan, have shown significant promise in treating advanced endometrial and lung cancers, respectively, outperforming standard chemotherapy in clinical trials.
2 newsrooms · 2 languages · since
Plus
What happened
- 01Sacituzumab tirumotecan extended median survival by nearly 7 months for advanced endometrial cancer patients.
- 02Izalontamab brengitecan nearly doubled disease control duration for EGFR-mutated lung cancer patients.
- 03Both Chinese-developed drugs demonstrated higher tumor shrinkage rates than standard chemotherapy.
- 04Sacituzumab tirumotecan showed a 32% reduction in mortality risk for endometrial cancer patients.
- 05Izalontamab brengitecan reduced the risk of progression or death by 60% in lung cancer patients.
- 06Access to these drugs in Israel depends on Ministry of Health decisions and budget.
Sacituzumab tirumotecan extended survival by nearly 7 months for endometrial cancer patients and improved tumor response rates. Izalontamab brengitecan nearly doubled the time disease remained controlled for EGFR-mutated lung cancer patients and showed higher response rates. These developments signal China's growing influence in pharmaceutical innovation, with potential future availability in Israel contingent on regulatory approvals and budget allocations.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- Centre1
- RightNone
- HarediNone
- ArabNone
- Other1
How it broke
See which of the 2 newsrooms broke it, and who waited